CD105及微血管密度与非小细胞肺癌的关系

目的:探讨非小细胞肺癌组织中微血管密度与肺癌临床病理特征之间的关系.方法:应用抗CD105抗体检测非小细胞肺癌组织中微血管密度(MVD).结果:对非小细胞肺癌的不同病理分级的MVD均数进行单因素方差分析,F=9.66,P＜0.05,组间均数比较有统计学意义.做趋势检验:F=18.35,p＜0.05,各组MVD均数随肿瘤分化程度的升高而减少,并呈线性趋势.有淋巴结转移组MVD( 76.52±11.66)与无淋巴结转移组MVD( 45.38± 10.54)比较差异有统计学意义(P＜0.05).结论:MVD与非小细胞肺癌的分化程度、淋巴结转移有关.     

肾细胞癌血管内皮生长因子及微血管密度的免疫组化研究

目的　探讨血管内皮生长因子（VEGF）和微血管生成与肾癌发展的关系。　方法　应用免疫组化技术检测46例肿瘤组织中的VEGF。　结果　46例肿瘤组织中VEGF阳性表达28例 (60.8%)、微血管密度（MVD）为63.64±33.20,均显著高于正常组织。VEGF、MVD与肿瘤的组织类型无关（P＞0.05),与肿瘤的组织学分级有关（P＜0.05);VEGF阳性组MVD明显高于阴性组(P＜0.05);有淋巴结转移组VEGF、MVD均高于无淋巴结转移组(P＜0.05);VEGF阳性组术后5年复发转移率明显高于阴性组（P＜0.01)。　结论　VEGF与肾癌的血管生成有关,VEGF和MVD可作为反映肾细胞癌生物学行为的指标之一。     

非小细胞肺癌淋巴结微转移的临床病理研究

目的 探讨免疫组化染色检测非小细胞肺癌淋巴结微转移的可行性。方法 将25例肺癌患者术中获取的淋巴结标本进行石蜡包埋,然后连续切片,6～10张不等,切片厚为5μm。选择第1和倒数第2张切片进行苏木精伊红染色,剩余切片用于免疫组化染色。免疫组化所选抗体为鼠抗人细胞角蛋白19单克隆抗体。结果 195枚淋巴结接受了苏木精伊红染色检查。9例患者共30枚淋巴结中发现有显性转移,无一例患者的淋巴结中检测出微转移。135枚苏木精伊红染色阴性的淋巴结又进行了免疫组化染色检查,有31枚淋巴结病理切片中显现出了癌微转移。16例常规病理PN0期患者中,5例患者肺门淋巴结出现了微转移;另9例常规病理PN1期患者中,4例出现了纵隔淋巴结的微转移,差异有统计学意义（x^2=52．900,P=0．0193）。结论 普通苏木精伊红染色能准确地检测出非小细胞肺癌淋巴结中的显性转移灶,而不易发现隐匿性微转移灶。免疫组化染色能提高非小细胞肺癌淋巴结微转移的检出率,并可对部分Ⅰ、Ⅱ期患者重新进行TNN分期。     

肾细胞癌中血管内皮生长因子的表达

目的 探讨肾癌组织中血管内皮生长因子的表达及其与肾癌生物学行为的关系。方法 应用单克隆鼠抗-VEGF抗体通过免疫组化SP法研究肾癌中血管内皮生长因子的表达。结果 60例肾癌组织中35例(58.3％)血管内皮生长因子阳性。血表达与组织学分级(P<0.05)和TNM分期(P<0.05)均明显相关。 结论 血管内皮生长因子表达对肾癌生物学行为有重要影响,设法抑制血管内皮生长因子有望成为肾癌治疗的另一有效方法。     

非小细胞肺癌组织中血管内皮生长因子和变异型细胞间黏附分子的表达

目的　了解血管内皮生长因子 (VEGF)、变异型细胞间黏附分子 (CD4 4v6 )在非小细胞肺癌 (NSCLC)组织中的表达。方法　采用链霉素抗生物素蛋白 过氧化物酶 (SP)免疫组织化学方法 ,分析VEGF、CD4 4v6在 35例Ⅰ～Ⅱ期、2 7例Ⅲ～Ⅳ期NSCLC患者的癌组织中的表达 ,其中 5 0例患者有淋巴结转移、12例患者无淋巴结转移 ,中、高分化 39例、低分化 2 3例 ;随访 1997年 1月至 1999年 7月期间治疗的 4 2例患者 ,计算 3年生存率 ,用Cox比例风险模型分析生存时间的影响因素。结果　VEGF、CD4 4v6在NSCLC组织中表达阳性率分别为 73% (45 /6 2 )、6 9% (43/6 2 ) ,均明显高于癌旁正常组织 (χ2 值分别为 2 4 2 0 7、2 5 186 ,P均 <0 0 1)。VEGF、CD4 4v6的表达与临床分期及有无淋巴结转移有明显相关 ,有淋巴结转移者的阳性率明显高于无淋巴结转移者 (χ2 值分别为 7 14 6、5 376 ,P均 <0 0 5 ) ;Ⅲ～Ⅳ期患者的VEGF、CD4 4v6阳性率均明显高于Ⅰ～Ⅱ期患者 (χ2 值分别为6 392、12 15 2 ,P均 <0 0 5 )。VEGF、CD4 4v6阳性患者的 3年生存率 ,均明显低于阴性患者 (χ2 值分别为 4 36、7 2 1,P均 <0 0 5 )。除TNM临床分期、有无淋巴结转移外 ,VEGF及CD4 4v6也为影响患者 3年生存率的独立因素。结论　VEGF、CD4 4     

前列腺癌血管内皮生长因子及微血管密度的免疫组化研究

应用免疫组化技术检测前列腺癌(ＰＣａ)组织中血管内皮生长因子(ＶＥＧＦ)的表达和肿瘤微血管密度(ＭＶＤ) ,探讨ＰＣａ组织中血管形成的机制 ,报告如下。材料与方法　采用 1990～ 1994年病理证实的前列腺癌组织标本 38例。年龄 45～ 85岁 ,平均 6 8岁。病理类型 :高分化腺癌 10例 ,低分化腺癌 12例 ,未分化癌 16例。 10例良性前列腺增生(ＢＰＨ)组织标本取自非肿瘤患者作为对照。采用免疫组织化学技术两步法 ,兔抗人ＶＥＧＦ多克隆抗体购自ＳａｎｔａＣｒｕｚ公司 ,鼠抗人ＶＷＦ单克隆抗体购自Ｄａｋｏ公司 ;二抗为Ｄａｋｏ公司 (ＴｈｅＤ…     

血管内皮生长因子和细胞黏附分子1在非小细胞肺癌组织中的表达

目的　探讨血管内皮生长因子和细胞黏附分子 1在非小细胞肺癌组织中的表达及与非小细胞肺癌侵袭转移和预后的关系。方法　采用免疫组织化学方法检测 86例非小细胞肺癌患者癌组织中血管内皮生长因子和细胞黏附分子 1的表达水平,并结合术后病理分型、病理分期和随访资料进行分析。结果　(1)鳞癌与腺癌患者间血管内皮生长因子与细胞粘附分子 1表达阳性率差异无统计学意义;Ⅰ、Ⅱ期患者间表达阳性率差异有统计学意义 [分别为 47% ( 16 /34 )与 73% ( 30 /41 ),59% (20 /34)与 29% (12 /41),P<0. 05, 0. 01]。(2)淋巴结转移者血管内皮生长因子表达阳性率高于淋巴结无转移者[78% (39 /50)与 47% (17 /36),χ2 =8. 73,P<0. 01],细胞黏附分子 1表达阳性率低于淋巴结无转移者[24% (12 /50)与 56% (20 /36),χ2 =8 92,P<0. 01];术后转移者血管内皮生长因子表达阳性率高于无转移者[90% (38 /42)与 41% (18 /44),χ2 =23 24,P<0 .01],细胞黏附分子 1的表达阳性率低于无转移者[ 21% ( 9 /42 )与 52% ( 23 /44 ),χ2 =8 75,P<0. 01];血管内皮生长因子表达阳性者的 5年生存率低于阴性者(7% 与 57 %,χ2 =28. 47,P<0. 01),细胞黏附分子 1表达阳性者的 5年生存率高于阴性者(53%与 11%,χ2 =24 98,P<0 .01)。(3)血管内皮     

血管内皮生长因子及微血管密度与胃癌进展的关系

目的：探讨血管内皮生长因子（VEGF）及微血管密度（MVD）与胃癌临床病理因素的关系。方法：应用免疫组织化学（SP）方法测定胃癌及胃良性病变中VEGF表达及MVD。结果：胃癌组VEGF表达阳性率为75．0％，胃良性病变组为5．0％（P＜0．05），未浸润浆膜层者为50．0％，浸润浆膜层者为95．5％（P＜0．05），有淋巴民移者为82．8％，无淋巴结转移者为54．5％（P＜0．05），伴有远处转移者为100％，不伴有远处转移者为71．0％（P＜0．05），pTNM分期属，I，II期者为53．1％，Ⅲ，Ⅳ期者为89．6％（P＜0．05），胃良性病变的MVD显著低于胃癌组（P＜0．001），浸润深度达浆膜层，有淋巴结转移和远处转移及pTNM属Ⅲ，Ⅳ期者的MVD显著升高，其差异有显著性意义，VEGF表达与MVD明显相关，结论：VEGF上调及MVD增加对胃癌生长具有促进作用。     

血管内皮生长因子C与细胞角蛋白19检测在Ⅰ期非小细胞肺癌中的临床研究

目的探讨血管内皮生长因子C(vascular endothelial growth factor-C,VEGF-C)表达、细胞角蛋白19(cytokeratin 19,CK19)检测在Ⅰ期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者生存分析中的意义。方法纳入青岛大学医学院附属医院2004年1月至2005年6月由同一组医师完成的NSCLC患者269例,均行标准肺叶切除+区域淋巴结清扫术,全部患者临床资料和随访资料完整,病理标本保留完善,手术前、后均未行放疗和化疗等辅助治疗。应用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连结法(S-P)检测癌组织标本中VEGF-C表达,以CK19标记检测肺门和纵隔淋巴结微转移的情况,结合患者临床资料、病理结果及随访数据进行统计学分析。结果269例患者的性别(Hc=1.722,P=0.084)、年龄(Hc=0.914,P=0.360)、吸烟情况(Hc=2.440,P=0.295)、病理类型(Hc=5.668,P=0.058)和肿瘤直径(Hc=0.165,P=0.920)间VEGF-C表达差异无统计学意义,不同病理分化程度间VEGF-C表达差异有统计学意义(Hc=29.178,P=0.000);患者CK19检测在性别(χ2=0.000,P=0.999)、年龄(χ2=0.005,P=0.999)、吸烟情况(χ2=2.294,P=0.317)、病理类型(χ2=0.573,P=0.289)、病理分化程度(χ2=2.927,P=0.231)和肿瘤大小(χ2=0.006,P=0.999)间差异无统计学意义;VEGF-C表达强度不同时5年生存率差异有统计学意义(χ2=37.318,P=0.000);CK19阳性和阴性表达5年生存率差异有统计学意义(χ2=39.987,P=0.000);VEGF-C表达与CK19阳性率之间差异有统计学意义(χ2=25.954,P=0.000)。结论 VEGF-C表达、CK19结果与Ⅰ期NSCLC患者术后5年生存率关系密切,VEGF-C、CK19检测有助于判断患者预后,并指导患者手术后辅助治疗,具有较大的临床意义。     

血管内皮生长因子和钙粘合素在非小细胞肺癌中的表达及临床意义

目的 探讨血管内皮生长因子（VEGF）和上皮钙粘合素（E－cd)在非小细胞肺癌（NSCLC）中的表达水平及癌细胞发生侵袭、转移过程中的意义。方法 采用超敏过氧化酶免疫组织化学法检测手术切除的43例NSCLC组织标本中VEGF和E－cd的表达水平。结果 VEGF在高分化和中低分化组的阳性表达率分别为60.0%和86.9%，E－cd在高分化和中低分化组的阳性表达率分别为65.0%和34.9%，伴有与不伴有癌旁转移的NSCLC病例间其VEGF和E－cd阳性表达水平差异均有显著性意义。结论 VEGF和E－cd的表达水平与NSCLC侵袭、转移密切相关。     

SH2-B在非小细胞肺癌中的表达

目的 观察SH2-B在非小细胞肺癌癌组织、癌旁组织、正常肺组织、结肠癌组织中的表达.方法 用免疫组织化学SP法检测36例非小细胞肺癌癌组织、癌旁组织、36例正常肺组织、14例结肠癌组织中SH2-B的表达.结果 SH2-B在非小细胞肺癌癌组织、癌旁组织、正常肺组织、结肠癌组织中阳性表达率分别为97%(35/36)、64%(23/36)、14%(5/36)、71%(10/14).SH2-B在阳性细胞表达数计分及染色强度计分,正常肺组织、癌旁组织、癌组织依次增强,各组比较差异有统计学意义(P＜0.05).结论 SH2-B异常活化在非小细胞肺癌癌变过程中可能发挥重要作用.     

趋化因子受体4、血管内皮生长因子在非小细胞肺癌组织中的表达及其意义

目的 探讨趋化因子受体4(CXCR4)、血管内皮生长因子(VEGF)在肺癌组织中的表达及意义.方法 应用免疫组织化学方法检测90例肺癌组织中CXCR4、VEGF的表达,包括39例伴淋巴结转移者.结果 CXCR4、VEGF蛋白在肺正常组织表达较低,在90例肺癌组织中CXCR4的阳性表达率高达61.1％ (55/90);VEGF的阳性表达率为76.7％ (69/90).CXCR4的表达与肺癌患者的年龄、性别无明显相关,而与分化程度、TNM分期、病理类型和淋巴结转移明显相关;VEGF的表达与肺癌患者的年龄、性别和病理类型无相关,而与分化程度、TNM分期和淋巴结转移有相关性.结论 CXCR4和VEGF在肺癌组织的高表达与肺癌侵袭转移的发生和淋巴结转移有关.     

非小细胞肺癌循环肿瘤细胞的定量检测意义

目的 探讨定量检测非小细胞肺癌病人肺静脉和外周静脉血循环肿瘤细胞与临床分期、治疗及预后监测的相关性.方法 选择25例非小细胞肺癌病人,10例良性肺疾病者(对照组)、健康志愿者10位.经CD326免疫磁珠阳性分选富集循环肿瘤细胞(CTCs)标本后,行CK-FITC、CD45PE荧光抗体标记,应用多参数流式细胞仪对CTCs进行定量检测.结果 25例非小细胞肺癌病人术中肺静脉血CTCs定量检测阳性率为64%(16/25例),明显高于外周静脉血CTCs阳性率40%(10/25例)的水平(P<0.05);Ⅰ期13例中外周血CTCs阳性3例(23.0%),肺静脉血CTCs阳性8例(61.5%).结论 非小细胞肺癌CTCs水平的定量检测是较为敏感的肿瘤进展、治疗反应和预后预测的评价指标;免疫磁珠富集联合流式细胞分析技术检测CTCs的敏感性和特异性较高,具有一定的临床应用前景.     

非小细胞肺癌循环肿瘤细胞的定量检测意义

Objective To investigate the sensitivity, specificity and clinical significance of detecting circulating tomor cells (CTCs) in NSCLC. Methods Twenty-five patients who undetwent surgical resection for NSCLC form Jan 2007 to Apr 2007 were in- cluded in this study. Control group included 10 patients with benign pulmonary diseses (2 case of hamartoma and 8 case of pulmonary tu berculosis) and 10 healthy volunteers. The pulmonary veins blood and peripheral vein blood were collected respectively. The CD326 immunomagnetic beads and CK-fluorescein isothiocyanate (CK-FITC) were served as the marker antibodies of CTCs. Firstly mononu- clear cell marked by minibeads conjugated with CD326, the mononuclear cells were enriched and separated though Magnetic-activated cell separation(MACS), then the positive separtion cells were marked by anti-CK-FTTC and anti-leukocyte antibody CD45-phyco- erythrine (anti-CD45-PE), finally those cells detected and analyzed by flow cytometry . Results For stage Ⅰ and stage Ⅱ patients (n= 16), CTCs were detected from peripheral vein blood of in 5 (5/16, 31.25%) and from pulmonary veins blood in 9 (9/16, 56.25%). For stage Ⅲ and stage Ⅳ, CTCs were detected from peripheral vein blood in 5 (5/9, 55.56%) and from pulmonary veins blood in 9(7/9,77.78%).For stage Ⅰ,CTCs were detected from peripheral vein blood in 3(3/13,23%)and from pulmo- nery veins blood in 8(8/13,61.54%).The whole CTCs positive detection rate from pilmonary veins blood was 64%(16/25)which higher than feom peripheral vein blood(40%,10/25)(P<0.05).Conclusion The method was set up by MACS combined with FCM to detect the CTCs of pulmonary veins blood and peripheral vein blood of patients.with NSCLC,MACS combined with FCM may improve detection rate of CTCs.This technique appears to be an efficient to detect circulating tumor cells and may be important for dinical practice in the future.     

非小细胞肺癌循环肿瘤细胞的定量检测意义

Objective To investigate the sensitivity, specificity and clinical significance of detecting circulating tomor cells (CTCs) in NSCLC. Methods Twenty-five patients who undetwent surgical resection for NSCLC form Jan 2007 to Apr 2007 were in- cluded in this study. Control group included 10 patients with benign pulmonary diseses (2 case of hamartoma and 8 case of pulmonary tu berculosis) and 10 healthy volunteers. The pulmonary veins blood and peripheral vein blood were collected respectively. The CD326 immunomagnetic beads and CK-fluorescein isothiocyanate (CK-FITC) were served as the marker antibodies of CTCs. Firstly mononu- clear cell marked by minibeads conjugated with CD326, the mononuclear cells were enriched and separated though Magnetic-activated cell separation(MACS), then the positive separtion cells were marked by anti-CK-FTTC and anti-leukocyte antibody CD45-phyco- erythrine (anti-CD45-PE), finally those cells detected and analyzed by flow cytometry . Results For stage Ⅰ and stage Ⅱ patients (n= 16), CTCs were detected from peripheral vein blood of in 5 (5/16, 31.25%) and from pulmonary veins blood in 9 (9/16, 56.25%). For stage Ⅲ and stage Ⅳ, CTCs were detected from peripheral vein blood in 5 (5/9, 55.56%) and from pulmonary veins blood in 9(7/9,77.78%).For stage Ⅰ,CTCs were detected from peripheral vein blood in 3(3/13,23%)and from pulmo- nery veins blood in 8(8/13,61.54%).The whole CTCs positive detection rate from pilmonary veins blood was 64%(16/25)which higher than feom peripheral vein blood(40%,10/25)(P<0.05).Conclusion The method was set up by MACS combined with FCM to detect the CTCs of pulmonary veins blood and peripheral vein blood of patients.with NSCLC,MACS combined with FCM may improve detection rate of CTCs.This technique appears to be an efficient to detect circulating tumor cells and may be important for dinical practice in the future.     

非小细胞肺癌循环肿瘤细胞的定量检测意义

Objective To investigate the sensitivity, specificity and clinical significance of detecting circulating tomor cells (CTCs) in NSCLC. Methods Twenty-five patients who undetwent surgical resection for NSCLC form Jan 2007 to Apr 2007 were in- cluded in this study. Control group included 10 patients with benign pulmonary diseses (2 case of hamartoma and 8 case of pulmonary tu berculosis) and 10 healthy volunteers. The pulmonary veins blood and peripheral vein blood were collected respectively. The CD326 immunomagnetic beads and CK-fluorescein isothiocyanate (CK-FITC) were served as the marker antibodies of CTCs. Firstly mononu- clear cell marked by minibeads conjugated with CD326, the mononuclear cells were enriched and separated though Magnetic-activated cell separation(MACS), then the positive separtion cells were marked by anti-CK-FTTC and anti-leukocyte antibody CD45-phyco- erythrine (anti-CD45-PE), finally those cells detected and analyzed by flow cytometry . Results For stage Ⅰ and stage Ⅱ patients (n= 16), CTCs were detected from peripheral vein blood of in 5 (5/16, 31.25%) and from pulmonary veins blood in 9 (9/16, 56.25%). For stage Ⅲ and stage Ⅳ, CTCs were detected from peripheral vein blood in 5 (5/9, 55.56%) and from pulmonary veins blood in 9(7/9,77.78%).For stage Ⅰ,CTCs were detected from peripheral vein blood in 3(3/13,23%)and from pulmo- nery veins blood in 8(8/13,61.54%).The whole CTCs positive detection rate from pilmonary veins blood was 64%(16/25)which higher than feom peripheral vein blood(40%,10/25)(P<0.05).Conclusion The method was set up by MACS combined with FCM to detect the CTCs of pulmonary veins blood and peripheral vein blood of patients.with NSCLC,MACS combined with FCM may improve detection rate of CTCs.This technique appears to be an efficient to detect circulating tumor cells and may be important for dinical practice in the future.     

非小细胞肺癌循环肿瘤细胞的定量检测意义

Objective To investigate the sensitivity, specificity and clinical significance of detecting circulating tomor cells (CTCs) in NSCLC. Methods Twenty-five patients who undetwent surgical resection for NSCLC form Jan 2007 to Apr 2007 were in- cluded in this study. Control group included 10 patients with benign pulmonary diseses (2 case of hamartoma and 8 case of pulmonary tu berculosis) and 10 healthy volunteers. The pulmonary veins blood and peripheral vein blood were collected respectively. The CD326 immunomagnetic beads and CK-fluorescein isothiocyanate (CK-FITC) were served as the marker antibodies of CTCs. Firstly mononu- clear cell marked by minibeads conjugated with CD326, the mononuclear cells were enriched and separated though Magnetic-activated cell separation(MACS), then the positive separtion cells were marked by anti-CK-FTTC and anti-leukocyte antibody CD45-phyco- erythrine (anti-CD45-PE), finally those cells detected and analyzed by flow cytometry . Results For stage Ⅰ and stage Ⅱ patients (n= 16), CTCs were detected from peripheral vein blood of in 5 (5/16, 31.25%) and from pulmonary veins blood in 9 (9/16, 56.25%). For stage Ⅲ and stage Ⅳ, CTCs were detected from peripheral vein blood in 5 (5/9, 55.56%) and from pulmonary veins blood in 9(7/9,77.78%).For stage Ⅰ,CTCs were detected from peripheral vein blood in 3(3/13,23%)and from pulmo- nery veins blood in 8(8/13,61.54%).The whole CTCs positive detection rate from pilmonary veins blood was 64%(16/25)which higher than feom peripheral vein blood(40%,10/25)(P<0.05).Conclusion The method was set up by MACS combined with FCM to detect the CTCs of pulmonary veins blood and peripheral vein blood of patients.with NSCLC,MACS combined with FCM may improve detection rate of CTCs.This technique appears to be an efficient to detect circulating tumor cells and may be important for dinical practice in the future.     

非小细胞肺癌循环肿瘤细胞的定量检测意义

Objective To investigate the sensitivity, specificity and clinical significance of detecting circulating tomor cells (CTCs) in NSCLC. Methods Twenty-five patients who undetwent surgical resection for NSCLC form Jan 2007 to Apr 2007 were in- cluded in this study. Control group included 10 patients with benign pulmonary diseses (2 case of hamartoma and 8 case of pulmonary tu berculosis) and 10 healthy volunteers. The pulmonary veins blood and peripheral vein blood were collected respectively. The CD326 immunomagnetic beads and CK-fluorescein isothiocyanate (CK-FITC) were served as the marker antibodies of CTCs. Firstly mononu- clear cell marked by minibeads conjugated with CD326, the mononuclear cells were enriched and separated though Magnetic-activated cell separation(MACS), then the positive separtion cells were marked by anti-CK-FTTC and anti-leukocyte antibody CD45-phyco- erythrine (anti-CD45-PE), finally those cells detected and analyzed by flow cytometry . Results For stage Ⅰ and stage Ⅱ patients (n= 16), CTCs were detected from peripheral vein blood of in 5 (5/16, 31.25%) and from pulmonary veins blood in 9 (9/16, 56.25%). For stage Ⅲ and stage Ⅳ, CTCs were detected from peripheral vein blood in 5 (5/9, 55.56%) and from pulmonary veins blood in 9(7/9,77.78%).For stage Ⅰ,CTCs were detected from peripheral vein blood in 3(3/13,23%)and from pulmo- nery veins blood in 8(8/13,61.54%).The whole CTCs positive detection rate from pilmonary veins blood was 64%(16/25)which higher than feom peripheral vein blood(40%,10/25)(P<0.05).Conclusion The method was set up by MACS combined with FCM to detect the CTCs of pulmonary veins blood and peripheral vein blood of patients.with NSCLC,MACS combined with FCM may improve detection rate of CTCs.This technique appears to be an efficient to detect circulating tumor cells and may be important for dinical practice in the future.     

非小细胞肺癌循环肿瘤细胞的定量检测意义

Objective To investigate the sensitivity, specificity and clinical significance of detecting circulating tomor cells (CTCs) in NSCLC. Methods Twenty-five patients who undetwent surgical resection for NSCLC form Jan 2007 to Apr 2007 were in- cluded in this study. Control group included 10 patients with benign pulmonary diseses (2 case of hamartoma and 8 case of pulmonary tu berculosis) and 10 healthy volunteers. The pulmonary veins blood and peripheral vein blood were collected respectively. The CD326 immunomagnetic beads and CK-fluorescein isothiocyanate (CK-FITC) were served as the marker antibodies of CTCs. Firstly mononu- clear cell marked by minibeads conjugated with CD326, the mononuclear cells were enriched and separated though Magnetic-activated cell separation(MACS), then the positive separtion cells were marked by anti-CK-FTTC and anti-leukocyte antibody CD45-phyco- erythrine (anti-CD45-PE), finally those cells detected and analyzed by flow cytometry . Results For stage Ⅰ and stage Ⅱ patients (n= 16), CTCs were detected from peripheral vein blood of in 5 (5/16, 31.25%) and from pulmonary veins blood in 9 (9/16, 56.25%). For stage Ⅲ and stage Ⅳ, CTCs were detected from peripheral vein blood in 5 (5/9, 55.56%) and from pulmonary veins blood in 9(7/9,77.78%).For stage Ⅰ,CTCs were detected from peripheral vein blood in 3(3/13,23%)and from pulmo- nery veins blood in 8(8/13,61.54%).The whole CTCs positive detection rate from pilmonary veins blood was 64%(16/25)which higher than feom peripheral vein blood(40%,10/25)(P<0.05).Conclusion The method was set up by MACS combined with FCM to detect the CTCs of pulmonary veins blood and peripheral vein blood of patients.with NSCLC,MACS combined with FCM may improve detection rate of CTCs.This technique appears to be an efficient to detect circulating tumor cells and may be important for dinical practice in the future.     

非小细胞肺癌循环肿瘤细胞的定量检测意义

Objective To investigate the sensitivity, specificity and clinical significance of detecting circulating tomor cells (CTCs) in NSCLC. Methods Twenty-five patients who undetwent surgical resection for NSCLC form Jan 2007 to Apr 2007 were in- cluded in this study. Control group included 10 patients with benign pulmonary diseses (2 case of hamartoma and 8 case of pulmonary tu berculosis) and 10 healthy volunteers. The pulmonary veins blood and peripheral vein blood were collected respectively. The CD326 immunomagnetic beads and CK-fluorescein isothiocyanate (CK-FITC) were served as the marker antibodies of CTCs. Firstly mononu- clear cell marked by minibeads conjugated with CD326, the mononuclear cells were enriched and separated though Magnetic-activated cell separation(MACS), then the positive separtion cells were marked by anti-CK-FTTC and anti-leukocyte antibody CD45-phyco- erythrine (anti-CD45-PE), finally those cells detected and analyzed by flow cytometry . Results For stage Ⅰ and stage Ⅱ patients (n= 16), CTCs were detected from peripheral vein blood of in 5 (5/16, 31.25%) and from pulmonary veins blood in 9 (9/16, 56.25%). For stage Ⅲ and stage Ⅳ, CTCs were detected from peripheral vein blood in 5 (5/9, 55.56%) and from pulmonary veins blood in 9(7/9,77.78%).For stage Ⅰ,CTCs were detected from peripheral vein blood in 3(3/13,23%)and from pulmo- nery veins blood in 8(8/13,61.54%).The whole CTCs positive detection rate from pilmonary veins blood was 64%(16/25)which higher than feom peripheral vein blood(40%,10/25)(P<0.05).Conclusion The method was set up by MACS combined with FCM to detect the CTCs of pulmonary veins blood and peripheral vein blood of patients.with NSCLC,MACS combined with FCM may improve detection rate of CTCs.This technique appears to be an efficient to detect circulating tumor cells and may be important for dinical practice in the future.